Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2026 | 03-2025 | 03-2024 | 03-2023 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,439 | 4,229 | 3,589 | 9,353 | 22 |
| Receivables | 27 | 31 | 218 | N/A | N/A |
| Inventories | 0 | 95 | 60 | N/A | 21 |
| TOTAL | $6,829 | $4,894 | $4,380 | $9,634 | $49 |
| Non-Current Assets | |||||
| PPE Net | 1,169 | 1,227 | 898 | N/A | N/A |
| Intangibles | 0 | 0 | 0 | 178 | 0 |
| Other Non-Current Assets | 327 | 307 | 206 | 0 | 0 |
| TOTAL | $1,496 | $1,533 | $1,104 | $178 | $N/A |
| Total Assets | $8,325 | $6,427 | $5,484 | $9,812 | $49 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 29 | 33 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 575 | 588 | 121 | 724 | 1,246 |
| TOTAL | $685 | $673 | $169 | $908 | $1,245 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | 38 | N/A |
| Other Non-Current Liabilities | 313 | 298 | 182 | 0 | 41 |
| TOTAL | $305 | $292 | $176 | $N/A | $N/A |
| Total Liabilities | $990 | $965 | $345 | $908 | $1,245 |
| Shareholders' Equity | |||||
| Common Shares | 15 | 4 | 3 | 2 | 1 |
| Retained earnings | -29,613 | -24,589 | -18,528 | -11,795 | -6,337 |
| Other shareholders' equity | 36,933 | 30,047 | 23,664 | 20,697 | 5,139 |
| TOTAL | $7,335 | $5,462 | $5,139 | $8,904 | $-1,197 |
| Total Liabilities And Equity | $8,325 | $6,427 | $5,484 | $9,812 | $49 |